All posts
-
HGTV Reveals Its 2025 Smart Home Beauty
HGTV’s Smart Home 2025 has been revealed, and it’s everything a dream home should be: stylish, smart, and full of Texas personality. Located in San Antonio, Texas, this modern home…
-
Edible aquatic robots could be eaten by fish to eliminate waste
If you’re launching a robotic right into the water atmosphere without any objective of fetching it, that crawler had much better be naturally degradable. Swiss researchers ha…
-
Differentiable physics-based system identification for robotic manipulation of elastoplastic materials
The International Journal of Robotics Study, Ahead of Publish. Robot control of volumetric elastoplastic deformable products, from foods such as dough to building products like cla…
-
Bavarian Nordic retains full-year guidance
The Danish vaccination firm keeps in mind large boosts in both crucial company legs in the initial quarter of the year. Nonetheless, the expectation stays the same.
-
Gubra maintains outlook despite revenue slide
Den samlede omsætning faldt med 12 pct. sammenlignet med samme kvartal sidste år.
-
Genmab maintains guidance despite 30% growth in Darzalex sales
Super vendor Darzalex accomplished sales of USD 450m in the very first 3 months of the year.
-
Zealand Pharma weighing options to market obesity drug faster after Roche deal
chief executive officer stresses, nonetheless, that the firm will certainly not be leaping via hoops.
-
WSA CEO: Product launches will compensate for tough market
WS-Audiology’s chief executive officer is positive that brand-new launches can save development and develop a “extremely solid 3rd and 4th quarter”.
-
After Danish factory closure: Xellia Pharmaceuticals will “definitely prefer” production in Europe
According to Sophie Løhde, Denmark’s federal government has “a solid concentrate on safeguarding the supply of anti-biotics”. Nonetheless, the Preacher of Health …
-
Novo Nordisk ready for full launch of obesity pill in the US after application
The tablet will be the first approved oral weight-loss treatment in the US. CEO says Novo Nordisk has clearly been ahead of the competition in this area.
